[go: up one dir, main page]

NO20051928L - Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer. - Google Patents

Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.

Info

Publication number
NO20051928L
NO20051928L NO20051928A NO20051928A NO20051928L NO 20051928 L NO20051928 L NO 20051928L NO 20051928 A NO20051928 A NO 20051928A NO 20051928 A NO20051928 A NO 20051928A NO 20051928 L NO20051928 L NO 20051928L
Authority
NO
Norway
Prior art keywords
carbonitriles
pyridine
tieno
thieno
kinase inhibitors
Prior art date
Application number
NO20051928A
Other languages
English (en)
Norwegian (no)
Other versions
NO20051928D0 (no
Inventor
Diane Harris Boschelli
Nan Zhang
Ana Carolina Barrios Sosa
Haris Durutlic
Biqi Wu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20051928D0 publication Critical patent/NO20051928D0/no
Publication of NO20051928L publication Critical patent/NO20051928L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20051928A 2002-11-25 2005-04-20 Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer. NO20051928L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42886202P 2002-11-25 2002-11-25
PCT/US2003/036206 WO2004048386A2 (fr) 2002-11-25 2003-11-14 Thieno[3,2-b]pyridine-6-carbonitriles et thieno[2,3-b]pyridine-5-carbonitriles en tant qu'inhibiteurs de proteine kinase

Publications (2)

Publication Number Publication Date
NO20051928D0 NO20051928D0 (no) 2005-04-20
NO20051928L true NO20051928L (no) 2005-08-19

Family

ID=32393469

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051928A NO20051928L (no) 2002-11-25 2005-04-20 Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.

Country Status (20)

Country Link
US (1) US6987116B2 (fr)
EP (1) EP1565474A2 (fr)
JP (1) JP2006509760A (fr)
KR (1) KR20050086770A (fr)
CN (1) CN1714092A (fr)
AR (1) AR042087A1 (fr)
AU (1) AU2003290802A1 (fr)
BR (1) BR0316534A (fr)
CA (1) CA2502614A1 (fr)
CL (1) CL2003002287A1 (fr)
EC (1) ECSP055802A (fr)
MX (1) MXPA05004744A (fr)
NI (1) NI200500089A (fr)
NO (1) NO20051928L (fr)
NZ (1) NZ540104A (fr)
RU (1) RU2005120018A (fr)
TW (1) TW200412950A (fr)
UA (1) UA81000C2 (fr)
WO (1) WO2004048386A2 (fr)
ZA (1) ZA200504238B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2006010264A1 (fr) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibiteurs de signalisation de recepteur du facteur de croissance endotheliale (vegf) et de recepteur de facteur de croissance des hepatocytes (hgf)
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1904504B1 (fr) 2005-05-20 2014-03-19 MethylGene Inc. Inhibiteur de la signalisation du recepteur vegf et hgf
EP1957498B1 (fr) * 2005-05-20 2017-02-15 MethylGene Inc. Inhibiteurs de la signalisation du récepteur vegf et du récepteur hgf
WO2007035428A1 (fr) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Inhibiteurs de la kinase met
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US8003662B2 (en) * 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
CN101378758A (zh) * 2006-02-08 2009-03-04 惠氏公司 经由钯介导的偶联反应制备7-烯基-3氰基喹啉
EP2032538A2 (fr) * 2006-06-08 2009-03-11 Array Biopharma, Inc. Quinolines et méthodes d'utilisation
ATE531720T1 (de) * 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
JP5349306B2 (ja) * 2006-08-21 2013-11-20 ジェネンテック， インコーポレイテッド アザベンゾチオフェニル化合物および使用方法
TW200821318A (en) * 2006-09-26 2008-05-16 Wyeth Corp Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
RU2346947C1 (ru) * 2007-08-13 2009-02-20 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУВПО "КубГТУ") Способ получения фурилгетарилметанов, содержащих тиено[2,3-b]пиридиновый фрагмент
AU2008293038B2 (en) * 2007-08-29 2013-08-29 Mirati Therapeutics, Inc. Inhibitors of protein tyrosine kinase activity
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2009093008A1 (fr) * 2008-01-21 2009-07-30 Ucb Pharma S.A. Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
EP2332536A1 (fr) 2008-03-05 2011-06-15 MethylGene Inc. Inhibiteurs d'activité de kinase de tyrosine de protéine
GB0811304D0 (en) * 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
CN102137847B (zh) * 2008-07-01 2015-06-10 健泰科生物技术公司 作为mek激酶抑制剂的二环杂环
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
CA2897333C (fr) 2013-01-15 2021-07-06 Incyte Corporation Composes de thiazolecarboxamide et de pyridinecarboxamide utiles comme inhibiteurs de kinases pim
KR101468207B1 (ko) * 2013-02-14 2014-12-01 한국화학연구원 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
EP3924050A1 (fr) 2019-02-13 2021-12-22 PTC Therapeutics, Inc. Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale
BR112021015853A2 (pt) 2019-02-13 2021-10-05 Ptc Therapeutics, Inc. Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar
US20220056043A1 (en) * 2019-02-19 2022-02-24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
CN114269753B (zh) * 2019-09-29 2024-03-05 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
US20240051968A1 (en) * 2021-02-05 2024-02-15 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
EP4483954A1 (fr) * 2023-06-29 2025-01-01 Masarykova Univerzita Thieno[3,2-b!pyridines substituées comme inhibiteurs de protéine kinases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45A (en) * 1836-10-11 Machine fob shelling cokm
EP0126970A3 (fr) 1983-04-27 1985-11-06 Beecham Group Plc Dérivés de thiénopyridine anxiolytiques et antidépresseurs
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
BR9814018A (pt) * 1997-11-11 2000-09-26 Pfizer Prod Inc Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
PT2253620E (pt) * 1998-09-29 2014-04-15 Wyeth Holdings Llc 3-cianoquinolinas substituídas como inibidores de proteínas tirosinas quinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
ATE264328T1 (de) * 1999-04-21 2004-04-15 Wyeth Corp Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
CA2396579A1 (fr) * 1999-12-29 2001-07-05 Wyeth Inhibiteurs tricycliques de proteine kinase
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
WO2001094353A1 (fr) * 2000-06-06 2001-12-13 Pfizer Products Inc. Derives de thiophene utilises comme agents anticancereux
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
US7253184B2 (en) * 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
CA2810339A1 (fr) 2001-08-10 2003-02-20 Novartis Ag Utilisation d'inhibiteurs c-src seuls ou en combinaison avec sti571 pour le traitement de leucemies

Also Published As

Publication number Publication date
BR0316534A (pt) 2005-10-04
MXPA05004744A (es) 2005-08-03
AR042087A1 (es) 2005-06-08
ECSP055802A (es) 2005-08-11
NZ540104A (en) 2007-05-31
ZA200504238B (en) 2009-09-30
JP2006509760A (ja) 2006-03-23
EP1565474A2 (fr) 2005-08-24
WO2004048386A9 (fr) 2005-07-14
CN1714092A (zh) 2005-12-28
WO2004048386A2 (fr) 2004-06-10
CA2502614A1 (fr) 2004-06-10
NI200500089A (es) 2006-01-11
AU2003290802A1 (en) 2004-06-18
UA81000C2 (en) 2007-11-26
KR20050086770A (ko) 2005-08-30
US6987116B2 (en) 2006-01-17
US20040138251A1 (en) 2004-07-15
TW200412950A (en) 2004-08-01
WO2004048386A3 (fr) 2004-10-07
RU2005120018A (ru) 2006-05-10
NO20051928D0 (no) 2005-04-20
CL2003002287A1 (es) 2005-01-14

Similar Documents

Publication Publication Date Title
NO20051928L (no) Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.
SG145744A1 (en) Process for the preparation of 4-amino-3- quinolinecarbonitriles
YU83302A (sh) Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi
YU17003A (sh) Spiroheterociklični nitrili upotrebljivi kao reverzibilni inhibitori cisteinskih proteaza
PL370802A1 (en) Polymorphs of clopidogrel hydrogensulfate
WO2002102313A3 (fr) Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
YU17402A (sh) Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza
ATE485300T1 (de) Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
WO2002087513A3 (fr) Inhibiteurs heterocycliques fusionnes de phosphodiesterase (pde) 7
HRP20020997A2 (en) Serine protease inhibitors
AU2003237305A1 (en) Process of preparation of olanzapine form i
EP1383769A4 (fr) Pyrazolo 3,4-d]pyrimidine-4-ones 6-substitutes utiles en tant qu'inhibiteurs de la kinase dependante des cyclines
HUP0303590A3 (en) Method for the production of 4,6-diaminopyrimido[5,4-d]pyrimidines
WO2004043379A3 (fr) Composes chimiques
NO20065489L (no) Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer
AU2003219661A1 (en) Thieno (3, 2-b) pyridones as antiviral compounds
WO2002076396A3 (fr) Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferatives
AU2002365211A1 (en) 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
DK1501838T3 (da) Fremgangsmåde til fremstilling af clopidogrel
PT1469853E (pt) Utilização de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)-tieno[2,3-d]pirimidina para o tratamento da incontinência urinária
EP1436279B8 (fr) Composes chimiques
MXPA02003042A (es) Proceso para prevenir formacion de incrustaciones.
DK1307460T3 (da) Fremgangsmåde til fremstilling af imidazo [1,2-c][2,3]benzodiazepiner og mellemprodukter ved fremstilling af disse
IL158928A0 (en) (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES
PL1963335T3 (pl) Proces wytwarzania olanzapiny

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application